文献速递性腺与生殖内分泌糖尿病

放血疗法不改善功能性高雄激素血症代谢结局

Iron Overload in Functional Hyperandrogenism: In a Randomized Trial, Bloodletting Does Not Improve Metabolic Outcomes.
PubMed 文献 · J Clin Endocrinol Metab · 2021-01-01

一项随机平行开放标签临床试验纳入33例接受炔雌醇环丙孕酮治疗的多囊卵巢综合征或特发性高雄激素血症女性,随机分入3次计划放血组或观察组。结果显示两组胰岛素敏感性指数变化无差异(MD 0.0,95%CI -1.6至1.6),糖尿病前期/糖尿病风险相似(OR 0.981,95%CI 0.712至1.351),放血组部分出现血红蛋白或红细胞压积轻度下降但无严重贫血。

要点

  • 计划放血未改善功能性高雄激素血症患者的胰岛素敏感性。
  • 放血组与观察组的糖尿病前期/糖尿病风险无显著差异。
  • 放血后少数出现Hb<120 g/L或Hct<0.36,但无Hb<110 g/L或Hct<0.34。

核心结论

  • 在功能性高雄激素血症女性中,计划放血不改善胰岛素敏感性。
  • 放血不降低糖尿病前期/糖尿病风险。

研究设计与样本

  • 随机、平行、开放标签临床试验,纳入33例多囊卵巢综合征或特发性高雄激素血症成人女性。
  • 所有参与者先接受3个月35 μg炔雌醇+2 mg醋酸环丙孕酮治疗,随后1:1随机至3次计划放血或观察9个月。

主要发现

  • 胰岛素敏感性指数变化在整体组或组间均无差异(MD 0.0,95%CI -1.6至1.6)。
  • 放血组与观察组糖尿病前期/糖尿病风险相似(OR 0.981,95%CI 0.712至1.351)。
  • 放血组4例(21.1%)Hb<120 g/L、2例(10.5%)Hct<0.36,但无Hb<110 g/L或Hct<0.34。

关键数值与推荐

  • 主要结局为胰岛素敏感性指数变化和糖尿病前期/糖尿病频率。
  • 安全性结局为放血后Hb<120 g/L和/或Hct<0.36的女性百分比。

临床怎么用

  • 对于接受COC治疗的功能性高雄激素血症女性,不推荐以改善胰岛素敏感性为目的进行计划放血。
  • 放血治疗需监测血红蛋白和红细胞压积,但本研究中未出现严重贫血。

局限性

  • 样本量较小(33例),可能影响统计效能。
  • 开放标签设计可能引入偏倚。
  • 随访时间较短(9个月),长期代谢影响未知。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Functional hyperandrogenism may be associated with a mild increase in body iron stores. Iron depletion exerts a beneficial effect on metabolic endpoints in other iron overload states. OBJECTIVES: (i) To determine the effect of iron depletion on the insulin sensitivity and frequency of abnormal glucose tolerance in patients with functional hyperandrogenism submitted to standard therapy with combined oral contraceptives (COC). ii) To assess the overall safety of this intervention. DESIGN: Randomized, parallel, open-label, clinical trial. SETTING: Academic hospital. PATIENTS: Adult women with polycystic ovary syndrome or idiopathic hyperandrogenism. INTERVENTION: After a 3-month run-in period of treatment with 35 μg ethinylestradiol plus 2 mg cyproterone acetate, participants were randomized (1:1) to 3 scheduled bloodlettings or observation for another 9 months. MAIN OUTCOME MEASURES: Changes in insulin sensitivity index and frequency of prediabetes/diabetes, and percentage of women in whom bloodletting resulted in plasma hemoglobin <120 g/L and/or hematocrit <0.36. RESULTS: From 2015 to 2019, 33 women were included by intention-to-treat. During the follow-up, insulin sensitivity did not change in the whole group of women or between study arms [mean of the differences (MD): 0.0 (95%CI: -1.6 to 1.6)]. Women in the experimental arm showed a similar odds of having prediabetes/diabetes than women submitted to observation [odds ratio: 0.981 (95%CI: 0.712 to 1.351)]. After bloodletting, 4 (21.1%) and 2 women (10.5%) in the experimental arm had hemoglobin (Hb) levels <120 g/L and hematocrit (Hct) values <0.36, respectively, but none showed Hb <110 g/L or Hct <0.34. CONCLUSIONS: Scheduled bloodletting does not improve insulin sensitivity in women with functional hyperandrogenism on COC.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Ortiz-Flores AE, Martínez-García MÁ, Nattero-Chávez L, et al. Iron Overload in Functional Hyperandrogenism: In a Randomized Trial, Bloodletting Does Not Improve Metabolic Outcomes. J Clin Endocrinol Metab. 2021. PMID: 33462622. doi:10.1210/clinem/dgaa978

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。